Her2和TopoⅡ在乳腺癌组织中的表达水平与新辅助化疗疗效的关系研究

Study on the Relationship between the Expression of Her2 and Topo Ⅱ in Breast Cancer with Neoadjuvant Chemotherapy

目的:研究Her2和TopoⅡ在乳腺癌组织中的表达水平与新辅助化疗疗效。方法:以数字法抽选本院乳腺癌组织标本68例,新辅助化疗前后均具有组织Her-2、TopoⅡ等检测实验报告资料,并与患者临床疗效进行对比分析。结果:经新辅助化疗后,Her-2阳性表达率由85.29%(58/68)下降到60.29%(41/68),TopoⅡ阳性表达率由92.65%(63/68)下降到80.88%(55/68)(P<0.05);在治疗有效的患者中,Her-2阳性组表达率26.83%(11/36)明显低于阴性组92.59%(25/36),TopoⅡ阳性组表达率45.45%(25/55)明显低于阴性组84.62%(11/13)(P<0.05),同组间Her2、TopoⅡ表达率比较差异有统计学意义(P<0.05);Her2和TopoⅡ在1、2、4年生存率阳性组均低于阴性组(P<0.05)。结论:Her2和TopoⅡ对乳腺癌化疗效果有一定指导作用,对于判断乳腺癌预后也有一定参考价值。

Objective： To study the curative effect of Her2 and TopoⅡ in breast cancer and the effect of neoadjuvant chemotherapy.Methods： 68 cases were selected in our hospital for breast cancer tissue samples from the digital method, detected Her-2, Topo II assay and compared with the clinical curative effect of the patients.Results：After neoadjuvant chemotherapy , the expression rate of HER-2 dropped from 85.29% （58 /68） to 60.29%（41/68）, the expression rate of TopoⅡ dropped from 92.65%（63 /68） down to 80.88% （55 /68） （P〈0.05）; in the effective treatment of patients,the expression rate of Her-2 positive group was 26.83%（11/36）, which was significantly lower than the negative group 92.59% （25/36）, the expression rate of To-po II positive group was 45.45%（25/55）,which was significantly lower than the negative group 84.62%（11 /13） （P〈0.05）, there were significant differences in the expression rates of Her 2 and Topo in the same group （P〈0.05）; Her2 and Topo II survival rate in positive group were lower than those in negative group in 1,2,4 （P〈0.05）.Conclusion： Her2 and Topo II have a certain guiding role in the breast cancer chemotherapy effect, and have certain reference value for judging the prognosis of breast cancer .